TGIF2 and melanoma: Recently, Krzeszinski et al. [16] demonstrated that the miR-34a-mediated inhibition of breast and melanoma bone metastases was attributed exclusively to inhibiting osteoclast activity through downregulation of Tgif2, essential for osteoclast function [16].